IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC

被引：2
|
作者：
Wang, Jie
Fan, Yun
Fang, Jian
He, Jianxing
Liu, Yunpeng
Tao, Min
Altorki, Nasser
Felip, Enriqueta
Wakelee, Heather
Vallieres, Eric
Belleli, Rossella
McNally, Virginia
Bennett, Elizabeth
Gitlitz, Barbara J.
Zhou, Caicun
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT239
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Wu, Y-L.
    Tsuboi, M.
    Grohe, C.
    John, T.
    Tarruella, M. Majem
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1549
  • [32] MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
    Therasse, P.
    Vansteenkiste, J. F.
    Zielinski, M.
    De Pas, T. M.
    Atanackovic, D.
    Sequist, L. V.
    Vallieres, E.
    Swisher, S.
    Adams, S.
    Passlick, B.
    Eberhardt, W. E. E.
    Grunenwald, D.
    Mok, T.
    Boyer, M.
    Katz, A.
    Douillard, J.
    Debois, M.
    Brichard, V. G.
    Altorki, N. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC)
    He, Jie
    Zhang, Xiangru
    Li, Junling
    Han, Baohui
    Liu, Yongyu
    Wu, Shixiu
    Kuang, Y.
    Shen, Yi
    Chen, Chun
    Wang, Qun
    Li, Qiang
    Ma, Haitao
    Xu, Shidong
    Xu, Shaofa
    Wang, P.
    Mao, Weimin
    Pang, Z.
    Hou, S.
    Yang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1318 - S1319
  • [34] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial (vol 41, pg 1830, 2023)
    Herbst
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (22) : 3877 - 3877
  • [35] Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101)
    Yamaguchi, Masafumi
    Tada, Hirohito
    Mitsudomi, Tetsuya
    Seto, Takashi
    Yokoi, Kohei
    Katakami, Nobuyuki
    Nakagawa, Kazuhiko
    Oda, Makoto
    Ohta, Mitsunori
    Sawa, Toshiyuki
    Yamashita, Motohiro
    Iked, Norihiko
    Saka, Hideo
    Higashiyama, Masahiko
    Nomori, Hiroaki
    Semba, Hiroshi
    Negoro, Shunichi
    Chiba, Yasutaka
    Shimokawa, Mototsugu
    Fukuoka, Masahiro
    Nakanishi, Yoichi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2216 - 2223
  • [36] Update of a phase III trial of adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC)
    Jie, He
    Han, Baohui
    Liu, Yongyu
    Wu, Shi Xiu
    Kuang, Yukang
    Shen, Yi
    Chen, Chun
    Wang, Qun
    Li, Qiang
    Ma Haitao
    Xu, Shaofa
    Xu, Shidong
    Wang, Ping
    Mao, Weimin
    Pang, Zuoliang
    Hou, Shengcai
    Yang, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.
    Calvo, Virginia
    Domine, Manuel
    Sullivan, Ivana
    Gonzalez-Larriba, Jose-Luis
    Ortega, Ana Laura
    Bernabe, Reyes
    Sala, Maria Angeles
    Campos, Begona
    De Castro, Javier
    Martin-Martorell, Paloma
    Bosch-Barrera, Joaquim
    Mielgo, Xabier
    Vila, Laia
    Casal, Joaquin
    Ros, Silver
    Aguillo, Maite Martinez
    Padilla, Airam
    Sandiego, Sergio
    Machado, Jonathan Aires
    Provencio-Pulla, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC)
    Rittmeyer, A.
    Solomon, B.
    Ahn, J. S.
    Barlesi, F.
    Dziadziuszko, R.
    Nishio, M.
    Shaw, A.
    Bordogna, W.
    Meyenberg, C.
    Wu, Y. L.
    PNEUMOLOGIE, 2020, 74 : S129 - S130
  • [39] Three-Year Safety, Tolerability, and Health- Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Shepherd, Frances A.
    de Marinis, Filippo
    Kato, Terufumi
    Wang, Qun
    Su, Wu-Chou
    Choi, Jin Hyuk
    Sriuranpong, Virote
    Melotti, Barbara
    Fidler, Mary J.
    Chen, Jun
    Albayaty, Muna
    Stachowiak, Marta
    Taggart, Sarah
    Wu, Yi-Long
    Tsuboi, Masahiro
    Herbst, Roy S.
    Majem, Margarita
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : 1209 - 1221
  • [40] A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.
    Jie, H.
    Xiangru, Z.
    Han, B.
    Liu, Y.
    Wang, Q.
    Xu, S.
    Sheng, Y.
    Li, Q.
    Wu, S.
    Chen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345